Cervical Cancer News and Research

RSS

Cancer is a disease in which cells in the body grow out of control. Cancer is always named for the part of the body where it starts, even if it spreads to other body parts later. When cancer starts in the cervix, it is called cervical cancer. The cervix is the lower, narrow end of the uterus. Also known as the womb, the uterus is where a baby grows when a woman is pregnant. The cervix connects the upper part of the uterus to the vagina (birth canal).

Cervical cancer is highly preventable in most Western countries because screening tests and a vaccine to prevent HPV infections are available. When cervical cancer is found early, it is highly treatable and associated with long survival and good quality of life.

Electronic prescribing decreases prescription errors

Should doctors around the country use e-prescribing to decrease prescription errors? A study led by physician-scientists from Weill Cornell Medical College found that health care providers using an electronic system to write prescriptions were seven times less likely to make errors than those writing their prescriptions by hand. The study appears today in the online edition of the Journal of General Internal Medicine.

27 Feb 2010

UCLA School of Nursing selects CytoCore's PadKit Collection Kit for comparative cytology study of cervical cancer

CytoCore Inc., the developer of cost-effective products used in the practice of cytology for the detection and diagnosis of cancer and cancer related diseases, announced today that PadKit® Collection Kit, a transport kit using an intralabial device for the collection of gynecological samples, has been selected by the UCLA School of Nursing as the sample collection system for a comparative cytology study of cervical cancer.

26 Feb 2010

A surgical cure for diabetic and obese patients

Dr. Francesco Rubino, chief of gastrointestinal metabolic surgery at NewYork-Presbyterian Hospital/Weill Cornell Medical Center, is now enrolling overweight and mildly obese patients -- those with a body mass index (BMI) of 28 to 35 -- in a study of gastric bypass surgery aimed at reversing Type 2 diabetes.

25 Feb 2010

USPSTF-recommended guidelines lead to decline in mammograms and early detection programs for women under 50

In some states women ages 40 to 49 have less access to mammograms since the U.S. Preventive Services Task Force (USPSTF) released its recommendations to change breast cancer screening guidelines last November, according to a recent survey conducted by the Avon Foundation for Women. The USPSTF recommended changing the current mammography screening guidelines for average risk women to begin biennial screening at age 50 instead of annual mammograms starting at age 40.

24 Feb 2010

Health Canada approves GARDASIL for prevention of genital warts in males

Today, Merck announced that Health Canada has approved GARDASIL(R) (Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Recombinant Vaccine) for boys and men nine through 26 years of age for the prevention of infection caused by HPV types 6, 11, 16, and 18 and genital warts caused by HPV types 6 and 11.

23 Feb 2010

USPSTF mammography recommendations: Avon Foundation for Women survey confirms states denying coverage

A recent Avon Foundation for Women survey confirms what the American College of Radiology and other experts warned would happen: states are using deeply flawed and widely discredited U.S. Preventative Services Task Force mammography recommendations to deny women coverage for mammograms, and many women are foregoing long proven, life-saving mammography care based on the mistaken USPSTF recommendations.

23 Feb 2010

Smokers, tobacco users and high alcohol consumers: Get mouths, gums and tongues checked for cancer

The National Basketball Association's (NBA) Denver Nuggets Coach George Karl announced today that he has been diagnosed with treatable neck and throat cancer. According to published media reports, Karl's physician says the coach has cancer of his right tonsil that has spread to a lymph node in his neck. The 58-year-old Karl, who is also a prostate cancer survivor, coached in the NBA's All-Star game this past weekend.

22 Feb 2010

News outlets examine HIV vaccine research, cervical cancer screening data presented at conference

Several news outlets examine the latest reports out of this week's Conference on Retroviruses and Opportunistic Infections (CROI) in San Francisco.

20 Feb 2010

P4P programs may be effective in incentivizing low performing physicians: Study

Pay-for-performance (P4P) programs are payment models that reward workers for meeting certain performance measures for quality and efficiency. In the healthcare setting, P4P programs use a variety of methods to reward physicians financially for achieving targets, including fee differentials and bonuses.

20 Feb 2010

Advaxis reports net income of $929,244 for year ended October 31, 2009

Advaxis, Incorporated, the live, attenuated Listeria monocytogenes immunotherapy company, today reported results for the fiscal year-ended October 31, 2009.

19 Feb 2010

HPV DNA testing vital in identification of cervical cancer

Roche Molecular Systems, Inc. announced today that preliminary data from its ATHENA (Addressing THE Need for Advanced HPV Diagnostics) trial support the importance of screening for human papillomavirus (HPV) genotypes that put women at highest risk for developing cervical cancer. ATHENA is a prospective, double-blind, multi-centered, 47,000-patient, U.S.-registration trial designed to demonstrate the effectiveness of HPV detection as part of a cervical cancer screening program.

18 Feb 2010

Phase III data reveals potential of Merck’s GARDASIL in preventing HPV and HPV-related cancers

Merck & Co., Inc. announced today that in new Phase III data, GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] was 77.5 percent (95 percent CI: 39.6, 93.3) efficacious against anal intraepithelial neoplasia (AIN) associated with human papillomavirus (HPV) types 6, 11, 16 and 18 in 16-to-26 year-old men who have sex with men. The data were presented at the European Research Organization on Genital Infection and Neoplasia (EUROGIN) conference in Monte Carlo, Monaco.

18 Feb 2010

Phase III study: GARDASIL prevents 77.5% of pre-cursor lesions to anal cancer

In a new phase III study, GARDASIL(R) (Quadrivalent Human Papillomavirus (Types 6, 11, 16 and 18) Recombinant Vaccine) prevented 77.5 per cent of anal intraepithelial neoplasia (AIN) associated with human papillomavirus (HPV) types 6, 11, 16 and 18 in 16-to-26 year-old men who have sex with men.

17 Feb 2010

Merck announces global sales of $27.4 billion for full-year 2009

Merck & Co., Inc. today announced financial results for the fourth quarter and the full year of 2009 which include the results of legacy Schering-Plough operations from the close of the merger on Nov. 3, 2009 through Dec. 31, 2009.

16 Feb 2010

Overall benefits of HPV vaccination or frequent screening are low for women over 41

The overall potential benefits of human papillomavirus (HPV) vaccinations or frequent HPV screenings for women over the age of 41 are low, concludes a new study published online February 15 in the Journal of the National Cancer Institute. The study found that the rate of new infections preventable by vaccination declines with age. Furthermore, new infections among women at any age typically do not progress to cervical intraepithelial neoplasia grade 2 (CIN 2) or CIN 3, the precursors for cervical cancer.

16 Feb 2010

Public health researchers at UNC to lead multi-state initiative to prevent cervical cancer

Asserting that no one should die from cervical cancer, public health researchers at the University of North Carolina at Chapel Hill are leading a multi-state initiative to prevent - or even eradicate - the disease.

16 Feb 2010

Annual Income Tax Check-Off for Breast and Cervical Research campaign launched

The Pennsylvania Breast Cancer Coalition has launched its annual Income Tax Check-Off for Breast and Cervical Research campaign to fund PA researchers. By simply checking YES on line 35 of the PA 40 tax form, any taxpayer can donate all or part of their state income tax refund to breast and cervical cancer research.

16 Feb 2010

Positive interim results from Helix BioPharma's Topical Interferon Alpha-2b Phase II pharmacokinetic study

Helix BioPharma Corp. today announced that the first ten patients that have been enrolled in its Phase II pharmacokinetic study of Topical Interferon Alpha-2b in patients with low-grade cervical lesions have completed the pharmacokinetic primary endpoint analyses with positive findings.

14 Feb 2010

QIAGEN N.V. enters into agreement to distribute Celera molecular multiplex assay

QIAGEN N.V. and Celera Corporation today announced an agreement under which QIAGEN will distribute a Celera molecular multiplex assay. The assay is the next generation version of QIAGEN’s ResPlex II assay for detection of respiratory pathogens.

From QIAGEN Manchester Limited 11 Feb 2010

sanofi-aventis reports 2009 fourth-quarter and full-year net earnings

Commenting on the Group's 2009 performance, sanofi-aventis Chief Executive Officer Christopher A. Viehbacher said, "2009 was the first year of implementation of our new strategy. Major steps have already been achieved in strengthening our growth platforms and reinforcing our R&D pipeline while delivering a double-digit EPS(1) growth".

10 Feb 2010

Cervical Cancer News and Research

Further Reading

Electronic prescribing decreases prescription errors

UCLA School of Nursing selects CytoCore's PadKit Collection Kit for comparative cytology study of cervical cancer

A surgical cure for diabetic and obese patients

USPSTF-recommended guidelines lead to decline in mammograms and early detection programs for women under 50

Health Canada approves GARDASIL for prevention of genital warts in males

USPSTF mammography recommendations: Avon Foundation for Women survey confirms states denying coverage

Smokers, tobacco users and high alcohol consumers: Get mouths, gums and tongues checked for cancer

News outlets examine HIV vaccine research, cervical cancer screening data presented at conference

P4P programs may be effective in incentivizing low performing physicians: Study

Advaxis reports net income of $929,244 for year ended October 31, 2009

HPV DNA testing vital in identification of cervical cancer

Phase III data reveals potential of Merck’s GARDASIL in preventing HPV and HPV-related cancers

Phase III study: GARDASIL prevents 77.5% of pre-cursor lesions to anal cancer

Merck announces global sales of $27.4 billion for full-year 2009

Overall benefits of HPV vaccination or frequent screening are low for women over 41

Public health researchers at UNC to lead multi-state initiative to prevent cervical cancer

Annual Income Tax Check-Off for Breast and Cervical Research campaign launched

Positive interim results from Helix BioPharma's Topical Interferon Alpha-2b Phase II pharmacokinetic study

QIAGEN N.V. enters into agreement to distribute Celera molecular multiplex assay

sanofi-aventis reports 2009 fourth-quarter and full-year net earnings

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News